(EMAILWIRE.COM, September 05, 2018 ) 'Systemic Lupus Erythematosus (SLE)-Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SLE in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Systemic Lupus Erythematosus (SLE) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Get Sample Copy of the Report: http://www.reportsweb.com/inquiry&RW00011660535/sample

The Systemic Lupus Erythematosus (SLE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Publisher report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, Lupus Nephritis prevalent cases, diagnosed cases and treatable cases) scenario of Systemic Lupus Erythematosus (SLE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Publisher, the total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 5, 76,232 and 850,000 in 7MM respectively, in the year 2016.

Table of Contents

1. Report Introduction 1
2. Systemic Lupus Erythematosus (SLE) Market Overview at a Glance 2
2.1. Market Share Distribution of Systemic Lupus Erythematosus (SLE) in 2017 2
2.2. Market Share Distribution of Systemic Lupus Erythematosus (SLE) in 2027 2
2.3. Total Prevalent Cases of Systemic Lupus Erythematosus (SLE)-by Country (2017) 3
2.4. Total Market by Region of Systemic Lupus Erythematosus (SLE) (2017 & 2027) 3
3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE) 10
3.1. Introduction 10
3.2. Risk Factors 10
3.3. Causes 11
3.4. Symptoms 12
3.5. Clinical Manifestations 13
3.6. Pathogenesis 17
3.7. Diagnosis 19
4. Epidemiology and Patient Population 26
4.1. Key Findings 26
4.2. Population and Forecast Parameters 27
4.3. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM 28
4.4. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM-By Region 29
4.5. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM-Distribution (2017) 30
4.6. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM-Distribution (2027) 30
6. Treatment Practices 75
6.1. Treatment Goals 75
6.2. Treatment Algorithm 76
7. Unmet Needs 80
8. Marketed Drugs 82
8.1. Benlysta: GlaxoSmithKline plc 82
8.1.1. Drug Description 82
8.1.2. Mechanism of Action 82
8.1.3. Regulatory Milestones 82
8.1.4. Advantages & Disadvantages 84
8.1.5. Safety and Efficacy of Benlysta 84
8.1.6. Product Profile 85

Place Direct Purchase order For Complete report @ http://www.reportsweb.com/inquiry&RW00011660535/discount

Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results